Dexrazoxane in children with cancer: From evidence to practice

Journal of Clinical Oncology

Volumn 33, Issue 24, 2015, Pages 2594-2596

  Kremer, Leontien C M ^a   Van Dalen, Elvira C ^a  

^a EMMA CHILDREN S HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

RAZOXANE;

CANCER PATIENT; CANCER SURVIVAL; CARDIOTOXICITY; CHILD; CHILDHOOD CANCER; CLINICAL PRACTICE; EDITORIAL; EVIDENCE BASED PRACTICE; HEART FAILURE; HEART PROTECTION; HUMAN; MEDICAL RECORD; OVERALL SURVIVAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; FEMALE; HODGKIN DISEASE; MALE; MORTALITY; PRECURSOR T-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA;

DEXRAZOXANE; FEMALE; HODGKIN DISEASE; HUMANS; MALE; PRECURSOR T-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA;

EID: 84940554758     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2015.61.7928     Document Type: Editorial

References (19)

1. van der Pal HJ, van Dalen EC, van Delden E, et al: High risk of symptomatic cardiac events in childhood cancer survivors. J Clin Oncol 30:1429-1437, 2012
2. Mulrooney DA, Yeazel MW, Kawashima T, et al: Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: Retrospective analysis of the Childhood Cancer Survivor Study cohort. BMJ 339:b4606, 2009
3. Ness KK, Hudson MM, Ginsberg JP, et al: Physical performance limitations in the Childhood Cancer Survivor Study cohort. J Clin Oncol 27:2382-2389, 2009
4. Mertens AC, Yasui Y, Neglia JP, et al: Late mortality experience in five-year survivors of childhood and adolescent cancer: The Childhood Cancer Survivor Study. J Clin Oncol 19:3163-3172, 2001
5. van Dalen EC, Caron HN, Dickinson HO, et al: Cardioprotective interventions for cancer patients receiving anthracyclines. Cochrane Database Syst Rev CD003917, 2011
6. Chow EJ, Asselin BL, Schwartz CL, et al: Late mortality after dexrazoxane treatment: A report from the Children's Oncology Group. J Clin Oncol 33:2639-2645, 2015
7. van Dalen EC, Raphaël MF, Caron HN, et al: Treatment including anthracyclines versus treatment not including anthracyclines for childhood cancer. Cochrane Database Syst Rev CD006647, 2014
8. Armenian SH, Hudson MM, Mulder RL, et al: Recommendations for cardiomyopathy surveillance for survivors of childhood cancer: A report from the International Late Effects of Childhood Cancer Guideline Harmonization Group. Lancet Oncol 16:e123-e136, 2015
9. Blanco JG, Sun CL, Landier W, et al: Anthracycline-related cardiomyopathy after childhood cancer: Role of polymorphisms in carbonyl reductase genes - A report from the Children's Oncology Group. J Clin Oncol 30:1415-1421, 2012
10. Visscher H, Ross CJ, Rassekh SR, et al: Pharmacogenomic prediction of anthracycline-induced cardiotoxicity in children. J Clin Oncol 30:1422-1428, 2012
11. van Dalen EC, van der Pal HJ, Caron HN, et al: Different dosage schedules for reducing cardiotoxicity in cancer patients receiving anthracycline chemotherapy. Cochrane Database Syst Rev CD005008, 2009
12. van Dalen EC, Michiels EM, Caron HN, et al: Different anthracycline derivates for reducing cardiotoxicity in cancer patients. Cochrane Database Syst Rev CD005006, 2010
13. Barry EV, Vrooman LM, Dahlberg SE, et al: Absence of secondary malignant neoplasms in children with high-risk acute lymphoblastic leukemia treated with dexrazoxane. J Clin Oncol 26:1106-1111, 2008
14. Schwartz CL, Constine LS, Villaluna D, et al: A risk-adapted, response-based approach using ABVE-PC for children and adolescents with intermediate- and high-risk Hodgkin lymphoma: The results of P9425. Blood 114:2051-2059, 2009
15. van Dalen EC, van den Berg H, Raphaël MF, et al: Should anthracyclines and dexrazoxane be used for children with cancer? Lancet Oncol 12:12-13, 2011
16. Tebbi CK, London WB, Friedman D, et al: Dexrazoxane-associated risk for acute myeloid leukemia/myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin's disease. J Clin Oncol 25:493-500, 2007
17. Salzer WL, Devidas M, Carroll WL, et al: Long-term results of the pediatric oncology group studies for childhood acute lymphoblastic leukemia 1984-2001: A report from the Children's Oncology Group. Leukemia 24:355-370, 2010
18. Andrews JC, Schünemann HJ, Oxman AD, et al: Guidelines: 15. Going from evidence to recommendation-determinants of a recommendation's direction and strength. J Clin Epidemiol 66:726-735, 2013
19. European Medicines Agency: European Medicines Agency recommends restricting the use of dexrazoxane-containing medicines. www.ema.europa.eu/docs/en-GB/document-library/Press-release/2011/06/WC500108013.pdf